REPEAT

Core One Labs’ Vocan Initiates Engineering and Design of a Proprietary Production System for Manufacturing of API-Grade DMT

VANCOUVER, British Columbia, April 21, 2021 (GLOBE NEWSWIRE) -- Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company” or ”Core One”) a life sciences research and technology company focused on bringing psychedelic medicines to market through novel delivery systems and psychedelic-assisted psychotherapy is pleased to announce its wholly owned subsidiary Vocan Biotechnologies Inc. (“Vocan”) has initiated the engineering and design of a proprietary enzymatic production system for the manufacturing of API-grade N,N-dimethyltryptamine (DMT).  DMT, a naturally occurring psychedelic substance, is currently under clinical investigation for the treatment of certain mood disorders. The compound is a primary component of traditional South American entheogenic brews and is traditionally derived from the leaves of a variety of plants endemic to equatorial regions across the globe.

The Vocan team has outlined a genetic pathway that could result in potentially elevated levels of DMT biosynthesis compared to the naturally occurring production pathway in the plants from which the compound is commonly extracted. With further development the research team plans to construct a high-throughput production system based on the same recombinant enzyme fermentation platform the company is already developing for API-psilocybin. The addition of this biosynthetic target to its development pipeline will allow Vocan to broaden its offerings of clinical-quality psychedelic medicines and enable advancement of the therapeutic use of psychedelic substances in medicine.

This proprietary approach to DMT production will preserve the highly specific molecular structure of naturally occurring plant-derived DMT and allow the Company’s fermentative biosynthesis platform to be optimized for maximum DMT output at production scale. The team intends to accelerate the current development stage of its DMT production system within a few weeks in order to fast-track the first DMT provisional patent filling with the US Patent and Trademark Office. Early patent protection of its proprietary DNA sequences and enhanced-activity enzymes will ensure API-grade DMT can be manufactured by a repeatable and reliable process without any requirement for more costly chemical synthesis or cultivation, extraction, and purification from plant sources.